Trial Condition(s):
Rosacea
Preferences & Treatment Satisfaction Drivers in Rosacea Patients
Study Completed
Trial Purpose
To survey patients with rosacea about their rosacea treatment preferences as well as to assess potential drivers of rosacea treatment satisfaction.
Inclusion Criteria
- Male or female patients of at least 18 years of age at index date - At least one prescription for a topical rosacea treatments: Azelaic Acid Gel, Azelaic Acid Cream, Metronidazole Gel, Metronidazole Cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel - At least one medical record with a diagnosis code for rosacea (ICD-9: 695.3) - At least 6 months of data history prior to the index date - Had at least one encounter at the Reliant Medical Group within 3 months prior to 01 January 2015
Exclusion Criteria
- None
Trial Summary
Enrollment Goal
206
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
Finacea (Azelaic Acid, BAY39-6251)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
Status
| Locations | Status | ||
|---|---|---|---|
Locations Investigative Site Boston, United States | Status Completed | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Trial Design
A Study of Patient Preferences and Drivers of Treatment Satisfaction in Patients with Rosacea
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Self-reported concerns and importance of such concerns regarding their current topical rosacea treatmentsAssessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all important and 10 meaning extremely importantTimeframe: Rosacea treatment in the past 4 weeks
Secondary Outcome
- Self-reported likelihood of switching to a topical rosacea treatmentsAssessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all likely and 10 meaning extremely likelyTimeframe: Rosacea treatment in the past 4 weeks
- Quality of lifeMeasured using Dermatology Life Quality Index (DLQI): The DLQI consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, and school, personal relationships and treatmentTimeframe: Rosacea treatment in the past 4 weeks
- Treatment satisfactionAssessed by a score on the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). Scores will be standardized and expressed as a 0-100 standardized scoreTimeframe: Rosacea treatment in the past 4 weeks
- Self-reported concerns and importance (a rating scale) of such concerns that patients would consider when switching to a new topical rosacea treatmentExtracted from the Rosacea Treatment Preference QuestionnaireTimeframe: Rosacea treatment in the past 4 weeks
Additional Information
Copyright © Bayer
Powered by
